Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome

Applied Sciences, Год журнала: 2022, Номер 12(6), С. 2941 - 2941

Опубликована: Март 13, 2022

The aim of this study was to investigate the application [18F]FDG PET/CT images-based textural features analysis propose radiomics models able early predict disease progression (PD) and survival outcome in metastatic colorectal cancer (MCC) patients after first adjuvant therapy. For purpose, 52 MCC who underwent [18F]FDGPET/CT during restaging process therapy were analyzed. Follow-up data recorded for a minimum 12 months PET/CT. Radiomics from each avid lesion PET low-dose CT images extracted. A hybrid descriptive-inferential method discriminant (DA) used feature selection predictive model implementation, respectively. performance predicting PD performed per-lesion analysis, per-patient liver lesions analysis. All again considered assess diagnostic discriminating lesions. In whole group patients, on among only GLZLM_GLNU selected, while three selected set. same resulted more accurately by associating with (AUROC 65.22%). stand-alone one (i.e., HUKurtosis) set selected. Focusing metastasis, recognized (GLZLM_GLNU) Similarly, we found (HUKurtosis). discrimination metastasis rest other lesions, optimal results imaging (SUVbwmin; AUROC 88.91%) two merged 95.33%). conclusion, our machine learning demonstrated be feasible potentially useful evaluation MCC.

Язык: Английский

---

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Frontiers in Medicine, Год журнала: 2022, Номер 9

Опубликована: Апрель 12, 2022

Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, use novel radiopharmaceuticals nuclear medicine can improve accuracy diagnosis staging, refine surveillance strategies choosing personalized treatment approaches, including radioligand therapy. Nuclear thus shows great promise for improving quality life patients by allowing non-invasive assessment diverse complex biological processes underlying development its evolution under This review aims to describe molecular probes currently clinical as well those investigation holding precision oncology cancer.

Язык: Английский

---

The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years

Current Medical Imaging Formerly Current Medical Imaging Reviews, Год журнала: 2023, Номер 19(8)

Опубликована: Фев. 17, 2023

Breast cancer is the most common malignancy in women, with high morbidity and mortality. Molecular alterations breast involve expression or upregulation of various molecular targets that can be used for diagnostic nuclear medicine imaging radiopharmaceutical treatment. Theragnostics based on binding radionuclides to targets. These induce a cytotoxic effect specific tumor cell (target) its vicinity, thus allowing personalized approach patients effective treatment comparably small side effects.This review aims describe promising currently under investigation theragnostics precision oncology cancer.A comprehensive literature search studies was performed PubMed, PMC, Scopus, Google Scholar, Embase, Web Science, Cochrane library databases, between 2010 2022, using following terms: neoplasm*, breast, cancer*, theragnostic*, theranostic*, radioligand therap*, RLT, MET, FLT, FMISO, FES, estradiol, trastuzumab, PD-L1, PSMA, FAPI, FACBC, fluciclovine, FAZA, GRPR, DOTATOC, DOTATATE, CXC4, endoglin, gastrin, mucin1, syndecan1.Fifty-three were included systematic summarized six clinical sections: 1) human epidermal growth factor receptor 2 (HER2); 2) somatostatin receptors (SSTRS); 3) prostate-specific membrane antigen radiotracers (PSMA); 4) fibroblast activation protein-α targeted radiotracers; 5) gastrin-releasing peptide receptor-targeted 6) other theragnostics.The theragnostic will progressively allow better patient selection, improve prediction response toxicity, avoiding unnecessary costly

Язык: Английский

---

The development process of ‘fit-for-purpose’ imaging biomarkers to characterize the tumor microenvironment

Frontiers in Medicine, Год журнала: 2024, Номер 11

Опубликована: Май 16, 2024

Immune-based treatment approaches are successfully used for the of patients with cancer. While such therapies can be highly effective, many fail to benefit. To provide optimal therapy choices and predict responses, reliable biomarkers assessment immune features in cancer significant importance. Biomarkers (BM) that enable a comprehensive repeatable tumor microenvironment (TME), lymphoid system, dynamics induced by drug fill this gap. Medical imaging, notably positron emission tomography (PET) magnetic resonance imaging (MRI), providing whole-body BMs, might deliver BMs. However, those BMs must well characterized as being ‘fit purpose’ intended use. This review provides an overview key steps involved development ‘fit-for-purpose’ applicable development, specific focus on pharmacodynamic assessing TME its modulation immunotherapy. The importance qualification according their context use (COU) defined Food Drug Administration ( FDA ) National Institutes Health Biomarkers, EndpointS, other Tools BEST glossary is highlighted. We elaborate how BM COU achieved.

Язык: Английский

---

Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons

Cancers, Год журнала: 2024, Номер 16(11), С. 1990 - 1990

Опубликована: Май 24, 2024

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized contemporary oncology, presenting efficacy in various solid tumors and lymphomas. However, ICIs may potentially overstimulate the system, leading to immune-related adverse events (irAEs). IrAEs affect multiple organs, such as colon, stomach, small intestine, kidneys, skin, lungs, joints, liver, lymph nodes, bone marrow, brain, heart, endocrine glands (e.g., pancreas, thyroid, or adrenal glands), exhibiting autoimmune inflammation. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is commonly used oncology for staging assessment of therapy responses, but it also serve a tool detecting irAEs. This review aims present patterns metabolic activation associated irAEs due ICI treatment, identifiable through 18F-FDG PET/CT. It describes advantages early detection irAEs, presents challenges differentiating them from tumor progression. delves into aspects molecular response within context pseudoprogression hyperprogression, along typical imaging findings related these phenomena. Lastly, summarizes role functional PET oncological immunotherapy, speculating on its future significance limitations.

Язык: Английский

---

Radiomic Models Predict Tumor Microenvironment Using Artificial Intelligence—the Novel Biomarkers in Breast Cancer Immune Microenvironment

Technology in Cancer Research & Treatment, Год журнала: 2023, Номер 22

Опубликована: Янв. 1, 2023

Breast cancer is the most common malignancy in women, and some subtypes are associated with a poor prognosis lack of efficacious therapy. Moreover, immunotherapy use other novel antibody‒drug conjugates have been rapidly incorporated into standard management advanced breast cancer. To extract more benefit from these therapies, clarifying monitoring tumor microenvironment (TME) status critical, but this difficult to accomplish based on conventional approaches. Radiomics method wherein radiological image features comprehensively collected assessed build connections disease diagnosis, prognosis, therapy efficacy, TME, etc In recent years, studies focused predicting TME using radiomics increasingly emerged, which demonstrate meaningful results show better capability than methods aspects. Beyond tumor-infiltrating lymphocytes, immunophenotypes, cytokines, infiltrating inflammatory factors, stromal components, radiomic models potential provide completely new approach deciphering facilitating by physicians.

Язык: Английский

---

Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET

EJNMMI Radiopharmacy and Chemistry, Год журнала: 2024, Номер 9(1)

Опубликована: Март 6, 2024

The brain is a challenging target for antibody-based positron emission tomography (immunoPET) imaging due to the restricted access of ligands through blood-brain barrier (BBB). To overcome this physiological obstacle, we have previously developed bispecific antibody that pass BBB via receptor-mediated transcytosis. While these radiolabelled high affinity and specificity, their long residence time in blood brain, typical large molecules, poses another challenge PET imaging. A viable solution could be two-step pre-targeting approach which involves administration tagged accumulates at site then clears from blood, followed by small molecule with fast kinetics. This can couple thereby make localisation visible vivo linkage achieved using inverse electron demand Diels-Alder reaction (IEDDA), trans-cyclooctene (TCO) tetrazine groups participating as reactants. In study, two novel

Язык: Английский

---

[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond

Clinical and Translational Imaging, Год журнала: 2023, Номер 11(5), С. 421 - 437

Опубликована: Июнь 17, 2023

Abstract In the era of precision medicine, optimization oncological patient management with early and accurate tumor response assessment is crucial. this scenario, [ 18 F]fluorodeoxyglucose ([ F]FDG) positron emission tomography/computed tomography (PET/CT) has gained an important role in providing prognostically relevant information. The first PET-based scoring system proposed 1999 was well-known European Organization for Research Treatment Cancer (EORTC) criteria. From that moment on over last 20 years, several PET/CT criteria have emerged been adapted to enhance specific types and/or therapies, only a few them endorsed by guidelines. literature systematic review, we aimed list discuss most solid non-solid F]FDG-avid tumors. A search extended until November 2022 PubMed/MEDLINE database conducted. used assess were classified according treatment type cancer type. Then, main findings analyzed discussed. widespread effort standardize identify best F]FDG PET tailored each emerged, also considering introduction new biological therapeutic agents increasingly essential post-treatment application different diseases. To improve their impact daily clinical practice, however, need be further validated.

Язык: Английский

---

The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma

Drug Discovery Today, Год журнала: 2021, Номер 27(2), С. 422 - 435

Опубликована: Окт. 7, 2021

Язык: Английский

---

Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging

Frontiers in Oncology, Год журнала: 2022, Номер 12

Опубликована: Окт. 26, 2022

Objective The in vivo imaging of programmed death ligand 1 (PD-L1) can monitor changes PD-L1 expression and guide (PD-1) or PD-L1-targeted immune checkpoint therapy. A 99m Tc-labeled affibody molecular probe targeting the receptor was prepared evaluated its tracing effect PD-L1-overexpressing colon cancer. Methods by genetic recombineering. Tc labeling achieved sodium glucoheptonate an SnCl 2 system. rate, radiochemical purity, stability vitro were determined instant thin-layer chromatography; MC38-B7H1 (PD-L1-positive) MC38 (PD-L1-negative) cancer cells used to evaluate affinity cell-binding experiments. biodistribution then C57BL/6J mice bearing tumors, tumor assessed with MC38-B7H1, double xenografts. Result nondecayed corrected yield Tc-PD-L1 95.95% ± 1.26%, showed good both phosphate-buffered saline (PBS) fetal bovine serum within 6 h. for assays 10.02 nmol/L. Single photon emission–computed tomography a rapid uptake tracer PD-L1-positive tumors very little retention PD-L1-negative control tumors. significantly retained kidneys bladder, suggesting that it is mainly excreted through urinary Heart, liver, lung, muscle tissue no significant radioactive retention. also renal retention, small amount thyroid gastrointestinal tract, blood clearance, tumor-to-blood radioactivity ratio peaked 120 min after drug injection. Conclusion we effectively target , clear quickly, obvious toxic side effects, which expected become new type detecting

Язык: Английский

---